Asset Details
Do you wish to reserve the book?
Recombinant Vaccinia/Fowlpox NY-ESO-1 Vaccines Induce Both Humoral and Cellular NY-ESO-1-Specific Immune Responses in Cancer Patients
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Recombinant Vaccinia/Fowlpox NY-ESO-1 Vaccines Induce Both Humoral and Cellular NY-ESO-1-Specific Immune Responses in Cancer Patients
Do you wish to request the book?
Recombinant Vaccinia/Fowlpox NY-ESO-1 Vaccines Induce Both Humoral and Cellular NY-ESO-1-Specific Immune Responses in Cancer Patients
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Recombinant Vaccinia/Fowlpox NY-ESO-1 Vaccines Induce Both Humoral and Cellular NY-ESO-1-Specific Immune Responses in Cancer Patients
2006
Overview
NY-ESO-1 is a cancer/testis antigen expressed in a range of human malignancies, and a number of vaccine strategies targeting NY-ESO-1 are being developed. In the present study, the safety and immunogenicity of recombinant vaccinia-NY-ESO-1 and recombinant fowlpox-NY-ESO-1 were analyzed in a series of 36 patients with a range of different tumor types. Each construct was first tested individually at two different dose levels and then in a prime-boost setting with recombinant vaccinia-NY-ESO-1 followed by recombinant fowlpox-NY-ESO-1. The vaccines were well tolerated either individually or together. NY-ESO-1-specific antibody responses and/or specific CD8 and CD4 T cell responses directed against a broad range of NY-ESO-1 epitopes were induced by a course of at least four vaccinations at monthly intervals in a high proportion of patients. CD8 T cell clones derived from five vaccinated patients were shown to lyse NY-ESO-1-expressing melanoma target cells. In several patients with melanoma, there was a strong impression that the natural course of the disease was favorably influenced by vaccination.
Publisher
National Academy of Sciences,National Acad Sciences
Subject
/ Antibody Formation - immunology
/ Antigens
/ Cancer
/ Cancer Vaccines - adverse effects
/ Cancer Vaccines - immunology
/ CD8-Positive T-Lymphocytes - immunology
/ Cells
/ Cytotoxicity, Immunologic - immunology
/ Epitopes
/ Humans
/ Immunity, Cellular - immunology
/ Melanoma
/ Membrane Proteins - immunology
/ Neoplasm Proteins - immunology
/ Peptide Fragments - immunology
/ Tumors
/ Vaccines
/ Vaccines, Synthetic - adverse effects
/ Vaccines, Synthetic - genetics
